What the EPISODE Trial Actually Changes in Treatment-Resistant Depression by PChina Jin LI (李锦) Psilocybin research in depression has become difficult to discuss without falling into one of two familiar narratives. In the first, psychedelics represent a long-awaited breakthrough: rapid, psychologically profound, and potentially transformative for patients who have not responded to conventional antidepressants. In…

Can Buprenorphine Sustain Ketamine's Antisuicidal Effect? by Kaida JIANG (江开达) Why This Combination Is Clinically Interesting Ketamine has changed the conversation about suicidal ideation in major depressive disorder because its effects can appear quickly. For patients in acute suicidal distress, speed is not a cosmetic advantage. Waiting weeks for a conventional antidepressant response can be…

Psychedelic Therapy vs Antidepressants: The Real Methodological Challenge Is Unblinding by PChina Jin LI (李锦) Why The Comparison Is Harder Than The Headline Suggests The debate over psychedelic-assisted therapy for depression is often framed as a contest: psychedelics versus antidepressants. In headlines, the question sounds simple. Which works better? Which produces larger reductions in depression…

Antidepressants in Pregnancy And The Risk To Offspring: What This Meta-Analysis Does — And Does Not — Show by PChina Jin LI (李锦) Why This Question Needs a Careful Reading Few medication questions are as emotionally charged as antidepressant use during pregnancy. The patient is not only thinking about symptom control. She may be thinking…

Types of Antidepressants: How SSRIs, SNRIs, NDRIs, Tricyclics, and Atypical Antidepressants Differ Reader-friendly overview This article compares the main antidepressant classes by mechanism, common examples, side-effect patterns, and the practical reasons a clinician may choose one class over another. SSRIs SNRIs NDRIs Tricyclics Atypical antidepressants Medical disclaimer This content is for educational purposes only. It…

Early Weeks on Psychiatric Medication: What Doctors Watch for After Starting Treatment Why The First 1–4 Weeks Matter The first few weeks after starting a psychiatric medication are often less about judging the final outcome and more about answering a more immediate question: is this treatment tolerable enough to continue? In many cases, benefits take…

From Weeks to Hours: How Rapid-Acting Antidepressants Are Changing Expectations in 2026 Introduction For much of modern psychiatry, time has been treated as an unavoidable constraint. Antidepressants were understood to require four to six weeks before meaningful improvement could be assessed, and this delay became embedded in clinical routines, treatment guidelines, and patient expectations. Clinicians…

Antidepressants without Guessing: How They Are Trying To Predict Treatment Response in 2026 Medically reviewed by John Smith, Jane Doe, Sarah Wilson Introduction For decades, prescribing antidepressants has followed a pattern that would feel out of place in most other areas of medicine. A clinician evaluates symptoms, considers comorbidities and prior history, selects a medication…

Antidepressants Are No Longer Just About Serotonin Medically reviewed by PChina Jin LI (李锦) Institute of toxicology, Academy of Military Medical Sciences, Beijing For several decades, the treatment of depression has been organized around a relatively simple biological idea: that mood disorders are primarily linked to disturbances in monoamine neurotransmitters, especially serotonin. This model, often…

Strong Heterogeneity in Physical Side Effects Between Antidepressants: Clinical Meaning of the 2025 Lancet Network Meta-Analysis by Darrel A. REGIER The Scope and Design of the Network Meta-Analysis The October 2025 Lancet network meta-analysis (NMA) represents one of the most comprehensive comparative assessments of physical side effects among antidepressants to date. By synthesizing data from…